DCG-IV
Из Википедије, слободне енциклопедије
 |
|
| (IUPAC) ime | |
|---|---|
| (1R,2R)-3-[(1S)-1-amino-2-hidroksi-2-oksoetil]ciklopropan-1,2-dikarboksilna kiselina | |
| Klinički podaci | |
| Identifikatori | |
| CAS broj | 147782-19-2 |
| ATC kod | nije dodeljen |
| PubHem | 5310979 |
| Hemijski podaci | |
| Formula | C7H9NO6 |
| Mol. masa | 203,149 g/mol |
| SMILES | eMolekuli & PubHem |
| Farmakoinformacioni podaci | |
| Trudnoća | ? |
| Pravni status | |
DCG-IV je lek koji se koristi u naučnim istraživanjima. On deluje kao agonist za grupu II metabotropnih glutamatnih receptora (mGluR2/3).[1] On ima potentne neuroprotektivne i antikonvulsantne efekte u životinjskim studijama.[2][3][4][5] On isto tako pokazuje antiparkinsonove efekte,[6][7] mada je poznato da usporava formiranje memorija.[8][9]
Reference [уреди]
- ^ Ishida M, Saitoh T, Shimamoto K, Ohfune Y, Shinozaki H (August 1993). „A novel metabotropic glutamate receptor agonist: marked depression of monosynaptic excitation in the newborn rat isolated spinal cord“. British Journal of Pharmacology 109 (4): 1169–77. PMC 2175774. PMID 8401927.
- ^ Bruno V, Copani A, Battaglia G, Raffaele R, Shinozaki H, Nicoletti F (April 1994). „Protective effect of the metabotropic glutamate receptor agonist, DCG-IV, against excitotoxic neuronal death“. European Journal of Pharmacology 256 (1): 109–12. DOI:10.1016/0014-2999(94)90624-6. PMID 7517889.
- ^ Yoshioka H, Sugita M, Kinouchi H (September 2009). „Neuroprotective effects of group II metabotropic glutamate receptor agonist DCG-IV on hippocampal neurons in transient forebrain ischemia“. Neuroscience Letters 461 (3): 266–70. DOI:10.1016/j.neulet.2009.06.056. PMID 19549561.
- ^ Attwell PJ, Singh Kent N, Jane DE, Croucher MJ, Bradford HF (September 1998). „Anticonvulsant and glutamate release-inhibiting properties of the highly potent metabotropic glutamate receptor agonist (2S,2'R, 3'R)-2-(2',3'-dicarboxycyclopropyl)glycine (DCG-IV)“. Brain Research 805 (1-2): 138–43. DOI:10.1016/S0006-8993(98)00698-2. PMID 9733953.
- ^ Fei Z, Zhang X, Bai HM, Jiang XF, Wang XL (December 2006). „Metabotropic glutamate receptor antagonists and agonists: potential neuroprotectors in diffuse brain injury“. Journal of Clinical Neuroscience 13 (10): 1023–7. DOI:10.1016/j.jocn.2005.11.042. PMID 17113985.
- ^ Dawson L, Chadha A, Megalou M, Duty S (February 2000). „The group II metabotropic glutamate receptor agonist, DCG-IV, alleviates akinesia following intranigral or intraventricular administration in the reserpine-treated rat“. British Journal of Pharmacology 129 (3): 541–6. DOI:10.1038/sj.bjp.0703105. PMC 1571875. PMID 10711353.
- ^ Venero JL, Santiago M, Tomás-Camardiel M, Matarredona ER, Cano J, Machado A (2002). „DCG-IV but not other group-II metabotropic receptor agonists induces microglial BDNF mRNA expression in the rat striatum. Correlation with neuronal injury“. Neuroscience 113 (4): 857–69. DOI:10.1016/S0306-4522(02)00232-4. PMID 12182892.
- ^ Huang LQ, Rowan MJ, Anwyl R (February 1997). „mGluR II agonist inhibition of LTP induction, and mGluR II antagonist inhibition of LTD induction, in the dentate gyrus in vitro“. Neuroreport 8 (3): 687–93. DOI:10.1097/00001756-199702100-00022. PMID 9106748.
- ^ Sato T, Tanaka K, Ohnishi Y, Teramoto T, Irifune M, Nishikawa T (February 2004). „Inhibitory effects of group II mGluR-related drugs on memory performance in mice“. Physiology & Behavior 80 (5): 747–58. DOI:10.1016/j.physbeh.2003.12.010. PMID 14984810.
